WO2004011456A8 - Protein tyrosine kinase inhibitors - Google Patents

Protein tyrosine kinase inhibitors

Info

Publication number
WO2004011456A8
WO2004011456A8 PCT/CA2003/001162 CA0301162W WO2004011456A8 WO 2004011456 A8 WO2004011456 A8 WO 2004011456A8 CA 0301162 W CA0301162 W CA 0301162W WO 2004011456 A8 WO2004011456 A8 WO 2004011456A8
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitors
protein tyrosine
compounds
formula
Prior art date
Application number
PCT/CA2003/001162
Other languages
French (fr)
Other versions
WO2004011456A9 (en
WO2004011456A1 (en
Inventor
Wayne R Danter
Martyn Brown
George Ma
Ghenadie Rusu
Jianhua Zhong
Natalie Lazarowych
Stephen Houldsworth
Original Assignee
Wayne R Danter
Martyn Brown
George Ma
Ghenadie Rusu
Jianhua Zhong
Natalie Lazarowych
Stephen Houldsworth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne R Danter, Martyn Brown, George Ma, Ghenadie Rusu, Jianhua Zhong, Natalie Lazarowych, Stephen Houldsworth filed Critical Wayne R Danter
Priority to EP03771039A priority Critical patent/EP1542989B1/en
Priority to DE60313339T priority patent/DE60313339T2/en
Priority to CA2494061A priority patent/CA2494061C/en
Priority to AU2003250701A priority patent/AU2003250701A1/en
Priority to US10/522,944 priority patent/US7585866B2/en
Publication of WO2004011456A1 publication Critical patent/WO2004011456A1/en
Publication of WO2004011456A8 publication Critical patent/WO2004011456A8/en
Publication of WO2004011456A9 publication Critical patent/WO2004011456A9/en
Priority to US12/510,862 priority patent/US8252800B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to compounds of the Formula (I), the pharmaceutically acceptable salts and stereoisomers thereof, which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions in mammals. In said Formula (I), : n is an integer, preferably n is 1; R1 and R2 are independently selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i) and (j).
PCT/CA2003/001162 2002-07-31 2003-07-31 Protein tyrosine kinase inhibitors WO2004011456A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP03771039A EP1542989B1 (en) 2002-07-31 2003-07-31 Protein tyrosine kinase inhibitors
DE60313339T DE60313339T2 (en) 2002-07-31 2003-07-31 PROTEIN TYROSINE KINASE INHIBITORS
CA2494061A CA2494061C (en) 2002-07-31 2003-07-31 Protein tyrosine kinase inhibitors
AU2003250701A AU2003250701A1 (en) 2002-07-31 2003-07-31 Protein tyrosine kinase inhibitors
US10/522,944 US7585866B2 (en) 2002-07-31 2003-07-31 Protein tyrosine kinase inhibitors
US12/510,862 US8252800B2 (en) 2002-07-31 2009-07-28 Protein tyrosine kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39940802P 2002-07-31 2002-07-31
US60/399,408 2002-07-31

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10522944 A-371-Of-International 2003-07-31
US12/510,862 Continuation US8252800B2 (en) 2002-07-31 2009-07-28 Protein tyrosine kinase inhibitors

Publications (3)

Publication Number Publication Date
WO2004011456A1 WO2004011456A1 (en) 2004-02-05
WO2004011456A8 true WO2004011456A8 (en) 2004-08-05
WO2004011456A9 WO2004011456A9 (en) 2005-06-02

Family

ID=31188578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001162 WO2004011456A1 (en) 2002-07-31 2003-07-31 Protein tyrosine kinase inhibitors

Country Status (7)

Country Link
US (2) US7585866B2 (en)
EP (1) EP1542989B1 (en)
AT (1) ATE360015T1 (en)
AU (1) AU2003250701A1 (en)
CA (1) CA2494061C (en)
DE (1) DE60313339T2 (en)
WO (1) WO2004011456A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0114879A (en) * 2000-10-24 2003-08-12 Thomson Licensing Sa Method of Sizing an Inline Media Player Page
CA2494061C (en) 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
EP1551824B1 (en) * 2002-10-09 2007-12-12 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
US7300931B2 (en) 2004-12-28 2007-11-27 Kinex Pharmaceuticals, Llc Compositions for treating cell proliferation disorders
GB0611331D0 (en) 2006-06-09 2006-07-19 Exxonmobil Chem Patents Inc Transparent coextruded films and processes for making such films
EP2041071B1 (en) * 2006-06-29 2014-06-18 Kinex Pharmaceuticals, LLC Biaryl compositions and methods for modulating a kinase cascade
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
CN101679264A (en) 2007-03-16 2010-03-24 斯克里普斯研究学院 inhibitors of focal adhesion kinase
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CA2999321A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
GB0910537D0 (en) 2009-06-18 2009-07-29 Ivax Pharmaceuticals Ireland Inhaler
TW201103904A (en) * 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2011129936A2 (en) 2010-04-16 2011-10-20 Kinex Pharmaceuticals, Llc Compositions and methods for the prevention and treatment of cancer
CN102477009B (en) * 2010-11-23 2014-01-01 清华大学深圳研究生院 Substitutive (S)-benaldehyde sulfonyl pyrrolidine-3-amino derivative, and preparation method and application thereof
HUE037637T2 (en) 2012-08-30 2018-09-28 Athenex Inc N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl)pyridin-2-yl) acetamide as protein tyrosine kinase modulators

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225726B1 (en) 1985-11-08 1991-04-17 Glaxo Group Limited Indole derivatives
US5155110A (en) * 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
LU87766A1 (en) * 1990-07-20 1992-03-11 Oreal USE OF PYRIMIDINE 3-OXIDE DERIVATIVES FOR BRAKING HAIR LOSS AND TOPICAL COMPOSITIONS IMPLEMENTED
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
ES2108120T3 (en) * 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int MONO- AND BICYCLE BIS ARYLIC AND HETEROARILIC COMPOUNDS INHIBITING EGF AND / OR PDGF TYPHOSINE KINASE.
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) * 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH0558894A (en) 1991-08-27 1993-03-09 Kanegafuchi Chem Ind Co Ltd Antitumor agent
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP0600832A1 (en) 1992-11-27 1994-06-08 Ciba-Geigy Ag Derivatives of diamino benzoic and diamino phthalic acid und their use as protein linase inhibitors
US5618829A (en) * 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
US5612340A (en) * 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
US5656643A (en) * 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU686843B2 (en) * 1994-02-23 1998-02-12 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
US5691101A (en) * 1994-03-15 1997-11-25 Kabushiki Kaisha Toshiba Photosensitive composition
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
DE19501481A1 (en) * 1995-01-19 1996-07-25 Bayer Ag 2,8-disubstituted quinazolinones
US5932574A (en) * 1995-04-27 1999-08-03 Zeneca Limited Quinazoline derivatives
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
CA2222545A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AR004010A1 (en) * 1995-10-11 1998-09-30 Glaxo Group Ltd HETERO CYCLIC COMPOUNDS
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
ES2186908T3 (en) * 1996-07-13 2003-05-16 Glaxo Group Ltd HETEROCICICLES CONDENSED COMPOUNDS AS INHIBITORS OF PPROTEINA-TIROSINA-QUINASAS.
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
JP2000515136A (en) * 1996-07-13 2000-11-14 グラクソ、グループ、リミテッド Bicyclic heteroaromatics as protein tyrosine kinase inhibitors
AU720429B2 (en) * 1996-08-23 2000-06-01 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
ES2239779T3 (en) * 1996-10-02 2005-10-01 Novartis Ag PIRIMIDINE DERIVATIVES AND PROCEDURES FOR THE PREPARATION OF THE SAME.
CO4940418A1 (en) * 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US5856643A (en) * 1997-08-18 1999-01-05 Eaton Corporation Auxiliary contact operator for electrical switching apparatus
JPH1180131A (en) 1997-09-01 1999-03-26 Mitsubishi Chem Corp Ethynylpyrimidine derivative
US6184377B1 (en) * 1997-12-15 2001-02-06 Sepracor Inc. Compositions containing N-amino- and N-hydroxy-quinazolinones and methods for preparing libraries thereof
EP1054004B1 (en) * 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
AU2173899A (en) * 1998-02-06 1999-08-23 De Montfort University Hydroxylation activated prodrugs
JP2002513008A (en) * 1998-04-29 2002-05-08 ジョージタウン ユニヴァーシティー Methods for identifying and using HLA-binding compounds as HLA-agonists and antagonists
US20010051628A1 (en) * 1998-05-04 2001-12-13 H.-J. Su Huang Methods to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors
US6253168B1 (en) * 1998-05-12 2001-06-26 Isis Pharmaceuticals, Inc. Generation of virtual combinatorial libraries of compounds
US6289352B1 (en) * 1998-05-29 2001-09-11 Crystal Decisions, Inc. Apparatus and method for compound on-line analytical processing in databases
CA2342222A1 (en) * 1998-08-31 2000-03-09 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
US20020010550A1 (en) * 1998-09-14 2002-01-24 George M. Grass Pharmacokinetic-based drug design tool and method
HU230728B1 (en) 1998-09-29 2017-12-28 Wyeth Holdings Llc Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
AU4972900A (en) 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
MXPA02001448A (en) 1999-08-12 2002-07-02 American Cyanamid Co Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer.
US6180836B1 (en) * 1999-08-17 2001-01-30 National Science Council Of Republic Of China Preparation of phenol via one-step hydroxylation of benzene catalyzed by copper-containing molecular sieve
SK3542002A3 (en) * 1999-09-15 2003-04-01 Warner Lambert Co Pteridinones as kinase inhibitors
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US6416940B2 (en) * 1999-11-10 2002-07-09 Eastman Kodak Company Calcium ion stable photographic color developing composition and method of use
ITMI992711A1 (en) * 1999-12-27 2001-06-27 Novartis Ag ORGANIC COMPOUNDS
HN2001000008A (en) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals AMIDA COMPOSITE AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES, AND THE INSTRUCTIONS FOR USE
US6405979B1 (en) * 2000-01-27 2002-06-18 Hughes Electronics Corp. Spacecraft protected by a coating including pyroelectric/ferroelectric particles, and the coating material
CN1362953A (en) * 2000-02-05 2002-08-07 沃泰克斯药物股份有限公司 Pyrazole compositions useful as inhibitors of ERK
US6313138B1 (en) * 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) * 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
DZ3308A1 (en) 2000-03-06 2001-09-27 Warner Lambert Co 5-alkylpyrido [2,3-d] pyrimidines tyrosine kinase inhibitors
GB0007657D0 (en) * 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
SE518840C2 (en) * 2000-04-19 2002-11-26 Microsoft Corp Procedure for providing access to data
GB2372562A (en) * 2000-04-26 2002-08-28 Ribotargets Ltd In silico screening
DE10023492A1 (en) * 2000-05-09 2001-11-22 Schering Ag New 2-(((hetero)aryl-alkyl)-amino)-aza-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
US6489094B2 (en) * 2000-05-31 2002-12-03 Pfizer Inc. Method and device for drug-drug interaction testing sample preparation
US7022484B2 (en) * 2000-06-08 2006-04-04 Board Of Regents, The University Of Texas System Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US20020012641A1 (en) * 2000-06-26 2002-01-31 Voorhees John J. Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin
US7067046B2 (en) * 2000-08-04 2006-06-27 Essen Instruments, Inc. System for rapid chemical activation in high-throughput electrophysiological measurements
US6647342B2 (en) * 2000-08-07 2003-11-11 Novodynamics, Inc. Knowledge-based process for the development of materials
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
ES2247187T3 (en) * 2000-10-17 2006-03-01 MERCK & CO., INC. ORALALLY ACTIVE SALTS CONNECTIVITY TYROSINE KINASE.
US7759323B2 (en) * 2001-05-22 2010-07-20 Eisai R & D Management Co., Ltd. Highly purified antiendotoxin compound
US7338675B2 (en) * 2002-05-10 2008-03-04 Tsi Health Sciences, Inc. Fenugreek seed bio-active compositions and methods for extracting same
CA2494061C (en) * 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
US20040193538A1 (en) * 2003-03-31 2004-09-30 Raines Walter L. Receipt processing system and method
US7764771B2 (en) * 2003-12-24 2010-07-27 Kimberly-Clark Worldwide, Inc. Method of recording invention disclosures

Also Published As

Publication number Publication date
US7585866B2 (en) 2009-09-08
AU2003250701A1 (en) 2004-02-16
EP1542989B1 (en) 2007-04-18
US20060069105A1 (en) 2006-03-30
DE60313339D1 (en) 2007-05-31
EP1542989A1 (en) 2005-06-22
DE60313339T2 (en) 2008-01-03
WO2004011456A9 (en) 2005-06-02
US8252800B2 (en) 2012-08-28
ATE360015T1 (en) 2007-05-15
US20090298855A1 (en) 2009-12-03
CA2494061C (en) 2011-06-14
CA2494061A1 (en) 2004-02-05
WO2004011456A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
WO2004011456A8 (en) Protein tyrosine kinase inhibitors
CA2492804A1 (en) Novel inhibitors of kinases
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
YU84603A (en) Novel tyrosine kinase inhibitors
WO2006050109A3 (en) Novel kinase inhibitors
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
EA200300248A1 (en) BICYCLOPIRASOLES, ACTIVE AS KINASE INHIBITORS, METHOD OF THEIR RECEIVING AND INCLUDING THEIR PHARMACEUTICAL COMPOSITIONS
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
BG106465A (en) Tyrosine kinase inhibitors
BR0313176A (en) Pyrazole compositions useful as gsk-3 inhibitors
EA200701302A1 (en) 4- (N-PHYLENAMINO) QUINAZOLIN / -CHINOLINE AS THYROSINKINASE INHIBITORS
HK1087700A1 (en) Triazolopyridazines as protein kinases inhibitors
NO20062136L (en) Imidazopyrazintyrosin kinase inhibitors
CA2400447A1 (en) Kinase inhibitors
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
ATE371656T1 (en) HETEROARYL-PYRIMIDINE DERIVATIVES AS JAK INHIBITORS
WO2003084938A3 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
CA2417050A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
NO984081L (en) Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and method of preparation thereof
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
MXPA05013076A (en) Isoindolin-1-one compounds as kinase inhibitors.
MXPA05009151A (en) Heterocyclic kinase inhibitors.
DK1165544T3 (en) Substituted 1,4-dihydroindeno [1,2-c] pyrazoles as inhibitors of tyrosine kinase
WO2007027528A3 (en) 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-.receptor tyrosine kinases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
D17 Declaration under article 17(2)a
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2494061

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003771039

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGE 18, DESCRIPTION, REPLACED BY A NEW PAGE 18; AFTER RECTIFICATION OF OBVIOUS ERRORS AUTHORIZED BY THE INTERNATIONAL SEARCH AUTHORITY

WWP Wipo information: published in national office

Ref document number: 2003771039

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006069105

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10522944

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10522944

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWG Wipo information: grant in national office

Ref document number: 2003771039

Country of ref document: EP